Biotechnology patents | ip4inno module 6A (part iii)
This area of patent law, more than any other, is subject to caveats, provisos and prohibitions regarding what can be patented. Technologies using proteins, enzymes, genes and stem cells stand to benefit mankind with new medical treatments, but the public, law-makers and patent offices nevertheless insist on strict limits to patent exclusivity.
This excerpt from ip4inno Module 6A explains the European Patent Office's policies for what can be patented and what not, as well as considering the reasons for barring some inventions from patent protection. For anyone who advises companies in the biotechnology or life sciences sector, this virtual classroom recording is essential viewing.
The virtual classroom tutor is Rob Chapman, examiner at the European Patent Office.
|previous page||main page||next page|